Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Sikkerhet og effektivitet av ENTERPRISE 2-enhet i endovaskulær behandling av intrakranielle aneurismer (EMPOWER)

2. november 2026 oppdatert av: Medos International SARL

ENTERPRISE 2 Vascular Rekonstruksjon Device and Delivery System Registry: En multisenter, prospektiv, enarms observasjonsstudie for å evaluere sikkerheten og effektiviteten med enheten for å lette endovaskulær spoleembolisering av intrakranielle aneurismer

The study is designed to evaluate the safety and effectiveness of ENTERPRISE 2 vascular reconstruction device and delivery system (hereinafter referred to as ENTERPRISE 2) to facilitate endovascular coil embolization of intracranial aneurysms.

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Detaljert beskrivelse

This is a prospective, multicenter, single-arm observational study, in which enrolled patients will be implanted with the ENTERPRISE 2 for evaluation of safety and effectiveness of ENTERPRISE 2 in real-world applications.

The study population will consist of 164 patients with ruptured or unruptured intracranial aneurysms and a parent vessel diameter of ≥2.5 mm and ≤4 mm. All patients will be implanted with the study device.

The enrolled patients will be followed at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure.

The primary endpoint is the incidence of aneurysm recanalization (at 180 days) evaluated through digital subtraction angiography (DSA). Secondary effectiveness endpoints include incidence of aneurysm recanalization (at 1 year), successful stent/coil placement rate (immediately post procedure), aneurysm occlusion (immediately post procedure, at 180 days and 1 year), incidence of retreatment (at 30 and 180 days, and 1, 2, 3, 4 and 5 years). Safety evaluation include: incidence of disabling stroke or neurological death (at 180 days and 1 year), incidence of in-stent thrombosis (at 180 days and 1 year), and incidence of in-stent stenosis (at 180 days and 1 year). Exploratory endpoints include stent wall apposition performance (intra-procedure), first-time deployment success rate (intra-procedure) and duration of stent deployment (intra-procedure).

Studietype

Observasjonsmessig

Registrering (Faktiske)

164

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100070
        • Beijing Tiantan Hospital, Capital Medical University
      • Beijing, Beijing Municipality, Kina, 100029
        • Beijing Anzhen Hospital, Capital Medical University
    • Guangdong
      • Guangzhou, Guangdong, Kina
        • Zhujiang Hospital of Southern Medical University
    • Henan
      • Zhengzhou, Henan, Kina, 450052
        • The first affiliated hospital of Zhengzhou university
    • Hubei
      • Wuhan, Hubei, Kina, 430022
        • Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210008
        • Nanjing Drum Tower Hospital
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330006
        • The first affiliated hospital of Nanchang university
    • Liaoning
      • Shenyang, Liaoning, Kina, 110004
        • Shengjing Hospital of China Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina
        • Huashan Hospital Shanghai Medical college, Fudan University
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310007
        • Zhejiang Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

This study will be conducted in patients with unruptured or ruptured intracranial aneurysm with a parent vessel diameter of ≥2.5 mm and ≤4 mm.

Beskrivelse

Inclusion Criteria:

  1. Patient (or his/her legal representative) understands the nature of the procedure and provides voluntary written informed consent for the use of his/her peri-procedural and follow-up data;
  2. Aged between 18 years and 80 years of age the time of consent;
  3. Patient has been diagnosed with ruptured (Hunt-Hess Grade I-III) or unruptured intracranial aneurysm and requires the endovascular treatment;
  4. Parent vessel with a diameter of ≥2.5 mm and ≤4 mm;
  5. Patient is willing to return to the investigational site for the post-procedure follow-up evaluations.

Exclusion Criteria:

  1. Severe co-morbidity associated with a life-expectancy of less than twelve months as determined by the investigator;
  2. Poor clinical condition with modified Rankin Scale (mRS) score ≥4;
  3. Having prior or potential severe allergic reaction to contrast medium;
  4. Known allergies to any of the device components, including Enterprise 2 and PROWLER® SELECT™ Plus Infusion Catheter;
  5. Angiogram demonstrating that the aneurysm is not appropriate for endovascular treatment (i.e. severe intracranial vessel tortuosity, stenosis, intracranial vasospasm not responsive to medical therapy);
  6. Arteriovenous malformation (AVM) in the territory of the target aneurysm;
  7. Unsuitable for the antithrombotic and/or anticoagulant therapies;
  8. Implantation of an intracranial stent associated with aneurysm or symptom distribution within 12 weeks prior to signature of Informed Consent Form;
  9. Implantation of a carotid stent associated with aneurysm or symptom distribution within 12 weeks prior to signature of Informed Consent Form;
  10. Evidence of active infection;
  11. Pregnant or lactating women;
  12. Having participated in clinical studies of other investigational drugs or devices within 30 days prior to signature of Informed Consent Form, excluding epidemiological studies of observational nature or natural history or not involving intervention;
  13. Pre-planned staged procedure of target aneurysms.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
ENTERPRISE 2 group

The study population enrolled for this clinical study is "aneurysm patients who need stent-assisted coiling treatment", using ENTERPRISE 2 device.

The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of aneurysm recanalization
Tidsramme: at 180 days post procedure

Incidence of aneurysm recanalization (at 180 days) = number of target aneurysm recanalization (at 180 days) ÷ total number of target aneurysms receiving follow-up × 100%. The results of aneurysm angiography at 180-day follow-up will be obtained through DSA, and the post-procedure immediate aneurysm recanalization shown in angiograms will be graded as per the Raymond-Roy Classification Scale.

The Raymond-Roy Classification at each follow-up time point increased by ≥ one class relative to that immediately after the procedure is defined as recanalization (e.g., Class I immediately after the procedure, Class II at 180-day follow-up).

at 180 days post procedure

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of aneurysm recanalization
Tidsramme: at 1 year post procedure

Incidence of aneurysm recanalization (at 1 year) = number of target aneurysm recanalization (at 1 year) ÷ total number of target aneurysms receiving follow-up × 100%. The results of aneurysm angiography at 1 year follow-ups will be obtained through DSA or MRA or CTA.

at 1 year post procedure
Successful stent/coil placement rate
Tidsramme: immediately post procedure

Successful stent/coil placement rate = number of target aneurysms with successful stent/coil placement ÷ total number of target aneurysms× 100%.

Successful stent/coil placement is defined as successful stent deployment and successful delivery and placement of the coil at the target aneurysm assessed immediately post procedure through angiography.

immediately post procedure
Aneurysm occlusion
Tidsramme: immediately post procedure, at 180 days and at 1 year post procedure

Aneurysm occlusion rate = number of target aneurysms with Raymond-Roy Class I or II aneurysm occlusion÷ total number of target aneurysms× 100%.

The aneurysm occlusion will be assessed by classifying the post-procedure immediate aneurysm occlusion shown in angiograms based on the Raymond-Roy Classification.

immediately post procedure, at 180 days and at 1 year post procedure
Incidence of retreatment
Tidsramme: at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure

Incidence of retreatment = number of target aneurysms receiving retreatment during the follow-up ÷ total number of target aneurysms receiving follow-up ×100%.

Retreatment refers to any intervention to the target aneurysm after completing first stent-assisted coil embolization for the target aneurysm.

at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of disabling stroke or neurological death
Tidsramme: at 180 days, at 1 year post procedure

Incidence of disabling stroke or neurological death = number of patients with disabling stroke or neurological death ÷ total number of patients receiving follow-up × 100%.

Stroke is defined as rapidly developing clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours with no apparent cause other than of vascular origin, including ischemic stroke or hemorrhagic stroke (i.e., intraparenchymal hemorrhage (IPH), SAH, subdural hemorrhage (SDH), epidural hemorrhage (EDH)).

Disabling stroke is defined as mRS score ≥ 3 assessed at a minimum of 90 days (+/- 30 days) post-stroke event.

Neurological death, also called brain death, refers to irreversible loss of the capacity for consciousness combined with the irreversible loss of all brainstem functions, including the capacity to breathe.

at 180 days, at 1 year post procedure
Incidence of in-stent thrombosis
Tidsramme: at 180 days, at 1 year post procedure

Incidence of in-stent thrombosis = number of target aneurysms with parent vessel (in-stent) thrombosis during follow-up ÷ total number of target aneurysms receiving follow-up ×100%.

at 180 days, at 1 year post procedure
Incidence of in-stent stenosis
Tidsramme: at 180 days, at 1 year post procedure

Incidence of in-stent stenosis = number of target aneurysms with parent vessel (in-stent) stenosis during follow-up ÷ total number of target aneurysms receiving follow-up ×100%.

Mild, moderate, and severe in-stent stenosis is clinically defined as a stenosis of <33%, 33-67%, and ≥67%, respectively, comparing with non-stented parent vessel [43, 44]. In this study, moderate and severe in-stent stenoses (with a stenosis of ≥33%) of the parent vessel are defined as in-stent stenosis.

at 180 days, at 1 year post procedure

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Xinjian Yang, Professor, Beijing Tiantan Hospital
  • Hovedetterforsker: Shiqing Mu, Professor, Beijing Tiantan Hospital
  • Hovedetterforsker: Qingrong Zhang, Professor, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
  • Hovedetterforsker: Yuxiang Gu, Professor, Huashan Hospital Shanghai Medical college, Fudan University
  • Hovedetterforsker: Chuanzhi Duan, Professor, Southern Medical University, China
  • Hovedetterforsker: Shu Wan, Professor, Zhejiang Hospital
  • Hovedetterforsker: Bo Yu, Professor, Shengjing Hospital
  • Hovedetterforsker: Yang Wang, Professor, The First Affiliated Hospital of Nanchang University
  • Hovedetterforsker: Sheng Guan, Professor, The First Affiliated Hospital of Zhengzhou University
  • Hovedetterforsker: Wohua Zhao, Professor, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
  • Hovedetterforsker: Xinjian Yang, Professor, Beijing Anzhen Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

30. juli 2020

Primær fullføring (Faktiske)

22. april 2022

Studiet fullført (Faktiske)

26. juli 2026

Datoer for studieregistrering

Først innsendt

27. februar 2020

Først innsendt som oppfylte QC-kriteriene

27. februar 2020

Først lagt ut (Faktiske)

28. februar 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Johnson & Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere